This study shows that systemic delivery of ASOs targeting DUX4 is a promising therapeutic strategy for FSHD and strategies that further improve the ASO efficacy in skeletal muscle are warranted. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.